|
|
| | JNJ-7706621 Basic information |
| Product Name: | JNJ-7706621 | | Synonyms: | 4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide JNJ7706621;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]benzenesulfonamide;Aurora Kinase/Cdk Inhibitor;Aurora Kinase/Cdk Inhibitor - CAS 443797-96-4 - Calbiochem;CS-409;JNJ7706621; JNJ 7706621;Benzenesulfonamide, 4-[[5-amino-1-(2,6-difluorobenzoyl)-1H-1,2,4-triazol-3-yl]amino]-;4-[[5-Amino-1-(2,6-difluorobenzoyl)-1,2,4-triazol-3-yl]amino]benzenesulfonamide | | CAS: | 443797-96-4 | | MF: | C15H12F2N6O3S | | MW: | 394.36 | | EINECS: | | | Product Categories: | Inhibitor;Inhibitors | | Mol File: | 443797-96-4.mol |  |
| | JNJ-7706621 Chemical Properties |
| Melting point | 149-155℃ | | Boiling point | 676.6±65.0 °C(Predicted) | | density | 1.71 | | storage temp. | +2C to +8C | | solubility | Soluble in DMSO at 15mg/ml | | form | White solid | | pka | 9.80±0.12(Predicted) | | Sensitive | Light Sensitive |
| | JNJ-7706621 Usage And Synthesis |
| Description | JNJ-7706621 is a dual inhibitor of cyclin-dependent kinases (CDKs) and Aurora kinases. It potently inhibits Cdk1/cyclin B, Cdk2/cyclin A, Cdk2/cyclin E, Cdk3/cyclin E, Cdk4/cyclin D1, Cdk6/cyclin D1, Aurora A, and Aurora B in vitro (IC50s = 9, 4, 3, 58, 253, 175, 11, and 15 nM, respectively). It shows selectivity for these enzymes over a panel of other receptors and kinases, although it exhibits submicromolar inhibition of VEGF and FGF receptors, as well as GSK3β. JNJ-7706621 blocks the growth of a large variety of cancer cell lines (IC50 values range from 112 to 514 nM), with lower potency against normal cells (IC50 values between 3.67 and 5.42 μM). It induces the regression of A375 melanoma human tumor xenografts in mice. JNJ-7706621 is a substrate for the ATP-binding cassette transporter G2, also known as breast cancer resistance protein. | | Uses | JNJ-770662 is a broad spectrum inhibitor of cyclin-dependent kinases and aurora kinases including CDK1/Cyclin B, CDK2/Cyclin A, CDK2/Cyclin E, Aurora-A and Aurora-B. JNJ-770662 has been shown to induce growth suppression and mitotic defects, these results suggest that JNJ-7706621 could be useful for cell cycle analysis and therapy of various cancers, including Ewing''s sarcoma. | | Definition | ChEBI: 4-[[5-amino-1-[(2,6-difluorophenyl)-oxomethyl]-1,2,4-triazol-3-yl]amino]benzenesulfonamide is a sulfonamide. | | target | CDK1 |
| | JNJ-7706621 Preparation Products And Raw materials |
|